Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus MECLAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus MECLAN.
ACHROMYCIN vs MECLAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic